<DOC>
	<DOCNO>NCT00978913</DOCNO>
	<brief_summary>The primary aim study evaluate toxicity vaccine combination vaccine Cyclophosphamide , evaluate immune response induce vaccine . The secondary aim investigate clinical tumour response duration tumour immune response .</brief_summary>
	<brief_title>Transfected Dendritic Cell Based Therapy Patients With Breast Cancer Malignant Melanoma</brief_title>
	<detailed_description>Phase I trial . Single center study ; patient refer study center institution Denmark . 14 patient include phase I trial DC vaccination regime consist primary 6 biweekly intradermal injection transfected dendritic cell , follow monthly injection progression ; Cyclophosphamide use vaccine adjuvant . Defined procedure employ generation autologous dendritic cell clinical application classify laboratory . Unmobilized leukapheresis use isolation large-scale mononuclear cell , dendritic cell generate monocyte cytokine stimulation transfected mRNA encode hTERT , survivin p53 tumour express p53 . Frozen preparation dendritic cell prepare use automate cryopreservation . Each patient receive minimum 1x106 dendritic cell per treatment supplement Cyclophosphamide 50 mg twice day every second week . Toxicity include autoimmunity evaluate use Common Toxicity Criteria ( CTC ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Histological verify metastatic breast cancer malignant melanoma , progression 2 . ≥ 18 year 3. patient must habil 4 . Performance status ≤ 1 ZubrodECOGWHOscale 5 . Leukocytes platelet must ≥normal . Hg ≥ 6.0 6. creatinin must normal 7 . Liverparametre &lt; 2.5 x normal . Bilirubin &lt; 30 8 . Expected survival &gt; 3 month 9 . Informed consent 11 . At least one measurable lesion accord RECIST criterion . 1 . Indication chemotherapy 2 . Other malignancy 3 . Brain metastases 4. severe medical condition 5 . Acute/chronic infection ex . HIV , hepatitis , tuberculose 6 . Severe allergy 7 . Autoimmune disease 8 . Other treatment immune suppress agent , anticancer agent experimental drug 9 . Uncontrolled hypercalcemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>dendritic cell</keyword>
	<keyword>cancervaccine</keyword>
	<keyword>breast cancer</keyword>
	<keyword>malignant melanoma</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>